554 related articles for article (PubMed ID: 25969176)
21. Proposal of a new 18F-FDG PET/CT predictor of response in rectal cancer treated by neoadjuvant chemoradiation therapy and comparison with PERCIST criteria.
Maffione AM; Ferretti A; Chondrogiannis S; Rampin L; Marzola MC; Grassetto G; Capirci C; Colletti PM; Rubello D
Clin Nucl Med; 2013 Oct; 38(10):795-7. PubMed ID: 24107808
[TBL] [Abstract][Full Text] [Related]
22. PET-based treatment response evaluation in rectal cancer: prediction and validation.
Janssen MH; Öllers MC; van Stiphout RG; Riedl RG; van den Bogaard J; Buijsen J; Lambin P; Lammering G
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):871-6. PubMed ID: 21377810
[TBL] [Abstract][Full Text] [Related]
23. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
[TBL] [Abstract][Full Text] [Related]
24. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy.
Huang WY; Kao CH; Huang WS; Chen CM; Chang LP; Lee MS; Chao HL; Chiu CH; Lo CH; Jen YM
J Nucl Med; 2013 Oct; 54(10):1710-6. PubMed ID: 23970365
[TBL] [Abstract][Full Text] [Related]
25. Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype.
Groheux D; Majdoub M; Sanna A; de Cremoux P; Hindié E; Giacchetti S; Martineau A; de Roquancourt A; Merlet P; Visvikis D; Resche-Rigon M; Hatt M; Espié M
Radiology; 2015 Nov; 277(2):358-71. PubMed ID: 25915099
[TBL] [Abstract][Full Text] [Related]
26. Accuracy of
Valkema MJ; Noordman BJ; Wijnhoven BPL; Spaander MCW; Biermann K; Lagarde SM; Bennink RJ; Schreurs WMJ; Roef MJ; Hobbelink MGG; Janssen MJR; Graven LH; van Lanschot JJB; Valkema R
J Nucl Med; 2019 Nov; 60(11):1553-1559. PubMed ID: 30877177
[TBL] [Abstract][Full Text] [Related]
27. Role of SUV(max) obtained by 18F-FDG PET/CT in patients with a solitary pancreatic lesion: predicting malignant potential and proliferation.
Hu SL; Yang ZY; Zhou ZR; Yu XJ; Ping B; Zhang YJ
Nucl Med Commun; 2013 Jun; 34(6):533-9. PubMed ID: 23503000
[TBL] [Abstract][Full Text] [Related]
28. Prediction of occult lymph node metastasis by metabolic parameters in patients with clinically N0 esophageal squamous cell carcinoma.
Moon SH; Kim HS; Hyun SH; Choi YS; Zo JI; Shim YM; Lee KH; Kim BT; Choi JY
J Nucl Med; 2014 May; 55(5):743-8. PubMed ID: 24700884
[TBL] [Abstract][Full Text] [Related]
29. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
Kukar M; Alnaji RM; Jabi F; Platz TA; Attwood K; Nava H; Ben-David K; Mattson D; Salerno K; Malhotra U; Kanehira K; Gannon J; Hochwald SN
JAMA Surg; 2015 Jun; 150(6):555-62. PubMed ID: 25902198
[TBL] [Abstract][Full Text] [Related]
30. Predictive value of (18)FDG PET-CT for tumour response in patients with locally advanced rectal cancer treated by preoperative chemoradiotherapy.
Kim JW; Kim HC; Park JW; Park SC; Sohn DK; Choi HS; Kim DY; Chang HJ; Baek JY; Kim SY; Kim SK; Oh JH
Int J Colorectal Dis; 2013 Sep; 28(9):1217-24. PubMed ID: 23404344
[TBL] [Abstract][Full Text] [Related]
31. Prediction of tumor response after neoadjuvant chemoradiotherapy in rectal cancer using (18)fluorine-2-deoxy-D-glucose positron emission tomography-computed tomography and serum carcinoembryonic antigen: a prospective study.
Li QW; Zheng RL; Ling YH; Wang QX; Xiao WW; Zeng ZF; Fan W; Li LR; Gao YH
Abdom Radiol (NY); 2016 Aug; 41(8):1448-55. PubMed ID: 27116012
[TBL] [Abstract][Full Text] [Related]
32. Response to chemotherapy in gastric adenocarcinoma with diffusion-weighted MRI and (18) F-FDG-PET/CT: correlation of apparent diffusion coefficient and partial volume corrected standardized uptake value with histological tumor regression grade.
Giganti F; De Cobelli F; Canevari C; Orsenigo E; Gallivanone F; Esposito A; Castiglioni I; Ambrosi A; Albarello L; Mazza E; Gianolli L; Staudacher C; Del Maschio A
J Magn Reson Imaging; 2014 Nov; 40(5):1147-57. PubMed ID: 24214734
[TBL] [Abstract][Full Text] [Related]
33. Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy.
Pöttgen C; Levegrün S; Theegarten D; Marnitz S; Grehl S; Pink R; Eberhardt W; Stamatis G; Gauler T; Antoch G; Bockisch A; Stuschke M
Clin Cancer Res; 2006 Jan; 12(1):97-106. PubMed ID: 16397030
[TBL] [Abstract][Full Text] [Related]
34. Utility of MRI and PET/CT after neoadjuvant chemotherapy in breast cancer patients: correlation with pathological response grading system based on tumor cellularity.
Kim T; Kang DK; An YS; Yim H; Jung YS; Kim KS; Kang SY; Kim TH
Acta Radiol; 2014 May; 55(4):399-408. PubMed ID: 23963151
[TBL] [Abstract][Full Text] [Related]
35. 18F-FDG semi-quantitative parameters and biological prognostic factors in locally advanced breast cancer.
García Vicente AM; Soriano Castrejón A; Relea Calatayud F; Muñoz Madero V; Molina Garrido MJ; León Martín AA; Cordero García JM; Pilkington Woll JP; Chacón López-Muñiz I; Palomar Muñoz A
Rev Esp Med Nucl Imagen Mol; 2012; 31(6):308-14. PubMed ID: 23084013
[TBL] [Abstract][Full Text] [Related]
36. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer.
van Heijl M; Omloo JM; van Berge Henegouwen MI; Hoekstra OS; Boellaard R; Bossuyt PM; Busch OR; Tilanus HW; Hulshof MC; van der Gaast A; Nieuwenhuijzen GA; Bonenkamp HJ; Plukker JT; Cuesta MA; Ten Kate FJ; Pruim J; van Dekken H; Bergman JJ; Sloof GW; van Lanschot JJ
Ann Surg; 2011 Jan; 253(1):56-63. PubMed ID: 21233607
[TBL] [Abstract][Full Text] [Related]
37. Multifunctional profiling of non-small cell lung cancer using 18F-FDG PET/CT and volume perfusion CT.
Sauter AW; Winterstein S; Spira D; Hetzel J; Schulze M; Mueller M; Pfannenberg C; Claussen CD; Klotz E; Hann von Weyhern C; Horger MS
J Nucl Med; 2012 Apr; 53(4):521-9. PubMed ID: 22414637
[TBL] [Abstract][Full Text] [Related]
38. Comparison of restaging accuracy of repeat FDG-PET/CT with pelvic MRI after preoperative chemoradiation in patients with rectal cancer.
Huh JW; Kwon SY; Lee JH; Kim HR
J Cancer Res Clin Oncol; 2015 Feb; 141(2):353-9. PubMed ID: 25181962
[TBL] [Abstract][Full Text] [Related]
39. [Correlation between FDG PET /CT and the expression of glutl and ki-67 antigen in esophageal cancer].
Mu DB; Wang SP; Yang WF; Fu Z; Chen XX; Sun XR; Yu JM
Zhonghua Zhong Liu Za Zhi; 2007 Jan; 29(1):30-3. PubMed ID: 17575690
[TBL] [Abstract][Full Text] [Related]
40. Diffusion-weighted MRI and MR- volumetry--in the evaluation of tumor response after preoperative chemoradiotherapy in patients with locally advanced rectal cancer.
Birlik B; Obuz F; Elibol FD; Celik AO; Sokmen S; Terzi C; Sagol O; Sarioglu S; Gorken I; Oztop I
Magn Reson Imaging; 2015 Feb; 33(2):201-12. PubMed ID: 25460330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
